Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aprepitant + ondansetron is a fixed-dose combination of two antiemetic agents used together to prevent and treat nausea and vomiting, particularly those induced by cancer chemotherapy, radiation therapy, or surgery. Aprepitant is a selective high-affinity antagonist of the human substance P/neurokinin 1 (NK1) receptor, blocking the action of substance P in the central nervous system to prevent both acute and delayed emesis. Ondansetron is a selective serotonin 5-HT3 receptor antagonist that blocks serotonin both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone. The combination has demonstrated superior efficacy compared to monotherapy with either agent for preventing radiation-induced or chemotherapy-induced nausea and vomiting[4][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aprepitant + ondansetron.